Press Releases

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the journal Surgery Open Science, affiliated with the prestigious journal Surgery, recently published the largest real-world study from Germany, “A retrospective study assessing RefluxStop surgery for gastroesophageal reflux disease: Clinical outcomes in 79 patients from Germany (https://www.sciencedirect.com/science/article/pii/S2589845024001398)”.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, announces that on 23 December 2024 the company executed a directed share issue without payment to service parts of the equity incentive program for key employees.

Implantica AG (publ), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces it will join the Nasdaq First North 25 index effective January 2, 2025.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces that the leading Universitätsklinik Magdeburg, which is an INEK reporting hospital, now performs the RefluxStop™ procedure.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the completion of the onboarding of two new University Hospitals in Spain earlier this month, resulting in a total of ten leading RefluxStop™ Centers of Excellence in Spain.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the first RefluxStop™ procedures were completed this month by Dr Günther Sitzmann, head of General Surgery Department at Ospedale di Brunico, part of Azienda Sanitaria dell'Alto Adige, Brunico, Italy.

RefluxStop™ achieves crucial FDA milestone and leaps forward with strong momentum in both the US and Europe

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device RefluxStop™ for the treatment of acid reflux, a treatment field with 1 billion sufferers, announces the submission of the second clinical module of the Premarket Approval (PMA) application to the US FDA for RefluxStop™ along with responses to the FDA’s findings from the first module.

Implantica AG (publ) invites investors to a presentation of the third quarter 2024 at 15:00 CET on November 15. The interim report for the third quarter will be published at 8:00 a.m. CET on the same day.

Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, is pleased to report an impressive level of support from a large number of U.S. doctors who are interested to start with RefluxStop®* after launch, pending FDA approval, driven by the very solid clinical results from the 5-year CE-study and real world outcomes from multiple centers that mirror these excellent results.